{"id":8316,"date":"2025-04-04T00:05:18","date_gmt":"2025-04-03T22:05:18","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?post_type=story&p=8316"},"modified":"2026-02-16T22:04:03","modified_gmt":"2026-02-16T20:04:03","slug":"ensemble-contre-le-cancer-du-sein","status":"publish","type":"story","link":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/","title":{"rendered":"Ensemble contre le cancer du sein"},"content":{"rendered":"\n
\n
\n \n \n \n Entreprise <\/small>\n <\/a>\n \n \n

\n Ensemble contre le cancer du sein\n <\/h1>\n

Le cancer du sein est le cancer le plus fr\u00e9quent chez les femmes. Plus le cancer du sein est d\u00e9pist\u00e9 et trait\u00e9 pr\u00e9cocement, plus les chances de gu\u00e9rison sont \u00e9lev\u00e9es. Chez MSD, nous nous engageons \u00e0 renforcer le d\u00e9pistage et la d\u00e9tection pr\u00e9coce de ces cancers. C\u2019est pourquoi nous avons lanc\u00e9 en 2022 le PINK CUBE: une initiative de sensibilisation au cancer du sein, qui ne cesse de se d\u00e9velopper depuis. PINK CUBE a d\u00e9j\u00e0 re\u00e7u deux prix et cela fait notre fiert\u00e9!<\/p>\n <\/div>\n\n

\n

4. April 2025<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"PINK\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

Lors de la 6e Nuit du sponsoring au Kunsthaus de Zurich, en pr\u00e9sence d\u2019environ 280 invit\u00e9s, PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le Responsibility Award de SPONSORING SCHWEIZ. Cette distinction rend hommage \u00e0 PINK CUBE Test Your Breast en tant qu\u2019initiative unique et innovante, reposant sur des partenariats solides et des sponsors ayant un objectif commun: lutter contre le cancer du sein.<\/p>\n\n\n\n

PINK CUBE Test Your Breast<\/h2>\n\n\n\n

PINK CUBE Test Your Breast est une remarquable initiative visant \u00e0 sensibiliser la population au cancer du sein et au r\u00f4le important du d\u00e9pistage pr\u00e9coce. Dans le cadre du PINK CUBE, des gyn\u00e9cologues proposent des consultations et des examens de palpation gratuits des seins. Les visiteuses et visiteurs apprennent \u00e0 ressentir un nodule et \u00e0 palper leur poitrine de mani\u00e8re autonome pour d\u00e9tecter des changements.<\/p>\n\n\n\n

Par ailleurs, PINK CUBE Test Your Breast s\u2019engage par le biais d\u2019un travail m\u00e9diatique et d\u2019un dialogue avec le monde politique pour que tous les cantons de Suisse introduisent un programme organis\u00e9 de d\u00e9pistage par mammographie.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

R\u00e9sultats de\u00a02024<\/h2>\n\n\n\n

En octobre\u00a02024, \u00e0 l\u2019occasion du mois de la sensibilisation au cancer du sein, le container rose s\u2019est rendu dans cinq cantons et a diffus\u00e9 son important message sur le d\u00e9pistage pr\u00e9coce dans les m\u00e9dias aupr\u00e8s de plus de 2,7\u00a0millions de personnes.<\/p>\n\n\n\n

Pr\u00e8s de 500\u00a0personnes ont \u00e9t\u00e9 examin\u00e9es dans le PINK CUBE: d\u2019\u00e9ventuels signes de cancer du sein ont \u00e9t\u00e9 d\u00e9cel\u00e9s chez 32\u00a0femmes et 2\u00a0hommes. Dans le m\u00eame temps, PINK CUBE a contribu\u00e9 \u00e0 faire avancer les d\u00e9bats politiques sur l\u2019introduction de programmes de d\u00e9pistage par mammographie.<\/p>\n\n\n\n

C\u2019est seulement gr\u00e2ce \u00e0 une collaboration entre partenaires et au soutien du multi-sponsoring des entreprises MSD, Gilead, Roche, Exact Sciences, Novartis, Astra Zeneca et Eli Lilly que ces r\u00e9ussites ont pu voir le jour.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"Dimitri
Dimitri Gitas, Managing Director de MSD Suisse<\/figcaption><\/figure><\/div><\/div>\n\n\n\n
\n

<\/p>\n\n\n\n

\u201eNous sommes fiers d\u2019avoir mis sur pied cette importante initiative de sensibilisation au cancer du sein et de continuer \u00e0 la soutenir en tant que sponsor principal\u00bb, d\u00e9clare Dimitri Gitas, Managing Director de MSD Suisse. \u00abLe succ\u00e8s de PINK CUBE montre clairement qu\u2019un acc\u00e8s \u00e9gal \u00e0 la pr\u00e9vention et au d\u00e9pistage pr\u00e9coce du cancer est n\u00e9cessaire. C\u2019est un objectif qui peut \u00eatre atteint gr\u00e2ce \u00e0 une strat\u00e9gie nationale contre le cancer.\u201c<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Prise en charge des co\u00fbts de la mammographie dans le cadre du programme de d\u00e9pistage<\/h2>\n\n\n\n

Si un examen est r\u00e9alis\u00e9 dans le cadre d\u2019un programme de d\u00e9pistage, les co\u00fbts sont pris en charge par l\u2019assurance de base, sans imputation de la franchise. Les femmes qui participent ne paient que la franchise de 10% (env. 20 francs). Les femmes de plus de 50 ans re\u00e7oivent tous les deux ans par courrier des informations et une invitation \u00e0 passer une mammographie de d\u00e9pistage.\u00a0<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

PINK CUBE Test Your Breast 2025 sur les routes<\/h2>\n\n\n\n

En septembre et octobre 2025, le PINK CUBE se rendra dans les 11 cantons qui n\u2019ont pas encore mis en place de programme de d\u00e9pistage par mammographie.<\/p>\n\n\n\n

Informations compl\u00e9mentaires: www.pinkcube-testyourbreast.ch<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n

CH-NON-02963, 04\/2025<\/sup><\/p>\n\n\n\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Lors de la 6e Nuit du sponsoring au Kunsthaus de Zurich, en pr\u00e9sence d\u2019environ 280 invit\u00e9s, PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le Responsibility Award de SPONSORING SCHWEIZ. Cette distinction rend hommage \u00e0 PINK CUBE Test Your Breast en tant qu\u2019initiative unique et innovante, reposant sur des partenariats […]<\/p>\n","protected":false},"featured_media":8317,"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[],"content_topic":[46],"admin_field":[],"class_list":["post-8316","story","type-story","status-publish","has-post-thumbnail","hentry","content_topic-entreprise"],"yoast_head":"\nEnsemble contre le cancer du sein - msd.ch<\/title>\n<meta name=\"description\" content=\"PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le prix de la responsabilit\u00e9 de SPONSORING SCHWEIZ\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ensemble contre le cancer du sein - msd.ch\" \/>\n<meta property=\"og:description\" content=\"PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le prix de la responsabilit\u00e9 de SPONSORING SCHWEIZ\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-16T20:04:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2025\/04\/sponsoring-gv-award_1811.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"7395\" \/>\n\t<meta property=\"og:image:height\" content=\"4930\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/\",\"url\":\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/\",\"name\":\"Ensemble contre le cancer du sein - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\"},\"datePublished\":\"2025-04-03T22:05:18+00:00\",\"dateModified\":\"2026-02-16T20:04:03+00:00\",\"description\":\"PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le prix de la responsabilit\u00e9 de SPONSORING SCHWEIZ\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Stories\",\"item\":\"https:\/\/www.msd.ch\/fr\/stories-archive\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensemble contre le cancer du sein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\",\"url\":\"https:\/\/www.msd.ch\/fr\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s'engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ensemble contre le cancer du sein - msd.ch","description":"PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le prix de la responsabilit\u00e9 de SPONSORING SCHWEIZ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/","og_locale":"en_US","og_type":"article","og_title":"Ensemble contre le cancer du sein - msd.ch","og_description":"PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le prix de la responsabilit\u00e9 de SPONSORING SCHWEIZ","og_url":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/","og_site_name":"msd.ch","article_modified_time":"2026-02-16T20:04:03+00:00","og_image":[{"width":7395,"height":4930,"url":"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2025\/04\/sponsoring-gv-award_1811.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/","url":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/","name":"Ensemble contre le cancer du sein - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2025-04-03T22:05:18+00:00","dateModified":"2026-02-16T20:04:03+00:00","description":"PINK CUBE Test Your Breast a re\u00e7u le prestigieux prix du public et le prix de la responsabilit\u00e9 de SPONSORING SCHWEIZ","breadcrumb":{"@id":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.msd.ch\/fr\/stories\/ensemble-contre-le-cancer-du-sein\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Stories","item":"https:\/\/www.msd.ch\/fr\/stories-archive\/"},{"@type":"ListItem","position":2,"name":"Ensemble contre le cancer du sein"}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s'engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"extended_data":{"featured_image":"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2025\/04\/sponsoring-gv-award_1811.jpg?w=1024","acf_fields":{"mco_page_tracking_data":"","page_text_direction_selection":"ltr","show_section":true,"related_content_section_heading":"En savoir plus sur nous","heading_level":"","story_one_selection":"select","related_content_item_one":{"ID":2759,"post_author":"974","post_date":"2026-03-31 21:14:27","post_date_gmt":"2026-03-31 19:14:27","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"\u00c9tudes cliniques de MSD en Suisse\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"\\u0022Les \u00e9tudes cliniques sont la cl\u00e9 des nouvelles connaissances en termes de diagnostic et de traitement des maladies. Nous sommes fiers d\u2019y contribuer en Suisse.\\u0022\\r\\n\\r\\n\\u003cem\\u003eKlaudia Georgi, Sr. Director Clinical Research MSD Switzerland \\u0026amp; Serbia\\u003c\/em\\u003e\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":2760,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":{\"title\":\"Connaissances de base sur les \u00e9tudes cliniques\",\"url\":\"https:\/\/www.msd.ch\/fr\/home\/research\/clinical-trials\/\",\"target\":\"\"},\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"mco_hero_block_button_cta_aria_label\":\"\",\"_mco_hero_block_button_cta_aria_label\":\"mco_hero_block_button_cta_aria_label\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Notre travail en chiffres\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"preview\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group -->\n<div class=\"wp-block-group\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"40\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"essais cliniques en cours en Suisse\\r\\n(\u00e9tat 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"10\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"m\u00e9dicaments et vaccins de MSD, premiers de la classe th\u00e9rapeutique, enregistr\u00e9s en Suisse depuis 2010\\r\\n(\u00e9tat 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"173\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"millions de francs suisses investis dans la recherche depuis 2012\\r\\n(\u00e9tat: 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:acf\/content-block {\"name\":\"acf\/content-block\",\"data\":{\"maintain_image_aspect_ratio\":\"0\",\"_maintain_image_aspect_ratio\":\"content_block_maintain_image_aspect_ratio\",\"negative_style\":\"0\",\"_negative_style\":\"content_block_negative\",\"content_selection\":\"static\",\"_content_selection\":\"content_selction_method\",\"content_block_image\":9165,\"_content_block_image\":\"content_block_image\",\"content_block_heading\":\"La recherche clinique de MSD Suisse est coordonn\u00e9e depuis notre site de la R\u00f6sslimatt, \u00e0 Lucerne.\",\"_content_block_heading\":\"content_block_heading\",\"heading_level\":\"h3\",\"_heading_level\":\"content_block_heading_level\",\"content_block_body\":\"\",\"_content_block_body\":\"content_block_body\",\"content_block_cta\":{\"title\":\"Nos filiales\",\"url\":\"https:\/\/www.msd.ch\/fr\/home\/about-us\/sites\/\",\"target\":\"_blank\"},\"_content_block_cta\":\"content_block_cta\",\"content_block_aria_label\":\"\",\"_content_block_aria_label\":\"content_block_aria_label\",\"content_block_cta_button_style\":\"\",\"_content_block_cta_button_style\":\"content_block_cta_button_style_cf4f3fd32dc26ec4ba7a6c14e51289c8\",\"content_block_optional_cta\":\"\",\"_content_block_optional_cta\":\"content_block_optional_cta\",\"content_block_optional_cta_aria_label\":\"\",\"_content_block_optional_cta_aria_label\":\"content_block_optional_cta_aria_label\",\"content_block_optional_cta_button_style\":\"\",\"_content_block_optional_cta_button_style\":\"content_block_optional_cta_button_style_d7b3517ac72218a3fb8daa4bc7def7a4\",\"content_block_optional_tag\":\"\",\"_content_block_optional_tag\":\"content_block_optional_tag\",\"content_block_video\":\"\",\"_content_block_video\":\"content_block_video\",\"content_media_position\":\"left\",\"_content_media_position\":\"content_media_position\",\"brightcove_account_id\":\"\",\"_brightcove_account_id\":\"bright_cove_account_id\",\"content_block_video_accessible_name\":\"\",\"_content_block_video_accessible_name\":\"content_block_video_accessible_name\",\"content_block_play_button_accessible_name\":\"\",\"_content_block_play_button_accessible_name\":\"content_block_play_button_accessible_name\",\"content_block_popup_accessible_name\":\"\",\"_content_block_popup_accessible_name\":\"content_block_popup_accessible_name\",\"content_block_popup_close_button_accessible_name\":\"\",\"_content_block_popup_close_button_accessible_name\":\"content_block_popup_close_button_accessible_name\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":1} -->\n<h1 class=\"wp-block-heading has-text-align-center\">Le programme d\u2019\u00e9tudes cliniques de MSD en Suisse (\u00e9tat 01\/2026)<\/h1>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\"} -->\n<p class=\"has-text-align-center\">(publi\u00e9 sur <a href=\"http:\/\/www.clinicaltrials.gov\/\">www.clinicaltrials.gov<\/a>)<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8918,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"className\":\"mb-2\"} -->\n<figure class=\"wp-block-image size-full mb-2\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2026\/01\/2026-01-MSD-Carte-Programme-Etudes-Cliniques-Suisse_v2.png\" alt=\"Carte: Sites des \u00e9tudes cliniques de MSD Suisse (\u00e9tat 01\/2026)\" class=\"wp-image-8918\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de l'immunologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Maladie intestinale\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-7240-001 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis\\r\\n\\r\\nStudy centers: Bern, St. Gallen, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7240-008 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn\u2019s Disease\\r\\n\\r\\nStudy centers: Basel, Bern, St. Gallen, Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de l'infectiologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"VIH\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8527-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nPhase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis\\r\\n\\r\\nStudy centers: Basel, Bern, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-051 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591A-053 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Na\u00efve Participants\\r\\n\\r\\nStudy centers: Basel, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-054 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Open-label Clinical Study of Doravirine\/Islatravir (DOR\/ISL [100 mg\/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR\/ISL (100 mg\/0.75 mg) QD in a Phase 3 Clinical Study\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591B-060 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) Once-Daily\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lugano\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de la m\u00e9decine g\u00e9n\u00e9rale\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Maladie pulmonaire\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-5475-013 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease\\r\\n\\r\\nStudy centers: St. Gallen, Zurich, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7962-038 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH\\r\\n\\r\\nStudy center: Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de l'oncologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Cancer de l\u2019estomac\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1022-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Geneva, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003e\\u003cstrong\\u003eMK-5909-005 \u2013 recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Basel, Zurich, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-9999-U02A \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Bellinzona, Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"Cancer de l'\u0153sophage\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-3475-06B \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1\/PD-L1 Treatment: Substudy 06B.\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06C \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06D \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced\/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06E \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable\/Metastatic Esophageal Cancer: Substudy 06E\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06F \u2013 Study in start-up \\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L\/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: Substudy 06F\\r\\n\\r\\nStudy centers: Chur, Geneva\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"Cancer de la prostate\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2400-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)\\r\\n\\r\\nStudy centers: Aarau, Basel, Fribourg, Geneva, Zurich\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"Cancer de la t\u00eate et du cou\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-689\/KEYNOTE-689 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Geneva\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"Cancer de la vessie\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-676\/KEYNOTE-676 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"Cancer du poumon\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1084-007 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed\/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)\\r\\n\\r\\nStudy centers: Fribourg, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-019 \u2013 \\u003cspan class=\\u0022gray_text\\u0022\\u003erecruitment open\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery\\r\\n\\r\\nStudy centers: Lausanne, Fribourg, Frauenfeld, Chur\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-091\/KEYNOTE-091 -\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-B98 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1\/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: St. Gallen\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"Cancer du rein (Carcinome r\u00e9nal)\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-6482-011 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1\/L1 Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Chur, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"Cancer du sang (Tumeurs malignes h\u00e9matologiques)\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1026-003 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies\\r\\n\\r\\nStudy centers: Bellinzona, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2140-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)\\r\\n\\r\\nStudy centers: Baden, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-4280A-008 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)\\r\\n\\r\\nStudy centers: Bellinzona\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"Cancer du sein\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer\\r\\n\\r\\nStudy centers: Basel, Thun, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-012 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery\\r\\n\\r\\nStudy centers: Chur, Fribourg, Geneva, Thun, Zurich\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"Cancers gyn\u00e9cologiques\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-005 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-020 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer\\r\\n\\r\\nStudy centers: Basel, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-021 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021\/ENGOTov85\/GOG-3102)\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Geneva, Winterthur\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"M\u00e9lanome\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-054 \/ KEYNOTE-054 - \\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-716\/KEYNOTE-716 - \\u003cspan class=\\u0022green_text\\u0022\\u003erecruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"Tumeurs solides\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-0472-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced\/Metastatic Solid Tumors.\\r\\n\\r\\nStudy centers: Geneva, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-1084-001 - recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\nA Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, St. Gallen\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-587\/KEYNOTE-587 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eLong-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Basel, Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4884-001 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1 Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants with Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, Lausanne, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-7339-002 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Bellinzona\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":12,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>Aper\u00e7u des \u00e9tudes men\u00e9es dans toute la Suisse qui recherchent des participants: <a href=\"https:\/\/www.humanforschung-schweiz.ch\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.humanforschung-schweiz.ch<\/a><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:acf\/featured-banner-block {\"name\":\"acf\/featured-banner-block\",\"data\":{\"mco_featured_banner_negative\":\"1\",\"_mco_featured_banner_negative\":\"mco_featured_banner_negative_294ytohe\",\"image\":2806,\"_image\":\"mco_featured_banner_block_image\",\"image_alt_text\":\"\",\"_image_alt_text\":\"mco_featured_banner_block_image_alt_text\",\"title\":\"Nous aimerions redonner espoir aux personnes victimes d\u2019un cancer\",\"_title\":\"mco_featured_banner_block_title\",\"description\":\"Nous investissons dans le d\u00e9veloppement de m\u00e9dicaments oncologiques innovateurs pour aider les personnes victimes d\u2019une maladie canc\u00e9reuse.\",\"_description\":\"mco_featured_banner_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_featured_banner_block_content_label\",\"cta_one\":{\"title\":\"En savoir plus\",\"url\":\"https:\/\/www.msd.ch\/fr\/home\/about-us\/areas-of-focus\/oncology\/\",\"target\":\"_blank\"},\"_cta_one\":\"mco_featured_banner_block_cta_one\",\"cta_one_aria_label\":\"\",\"_cta_one_aria_label\":\"mco_featured_banner_block_cta_one_aria_label_dIweyH6epdW9l52\",\"cta_two\":\"\",\"_cta_two\":\"mco_featured_banner_block_cta_two\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00136, 03\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"\u00c9tudes cliniques de MSD en Suisse","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"clinical-trials-in-switzerland","to_ping":"","pinged":"","post_modified":"2026-03-31 21:14:37","post_modified_gmt":"2026-03-31 19:14:37","post_content_filtered":"","post_parent":8833,"guid":"https:\/\/vip2-msd.com\/switzerland\/?page_id=2759","menu_order":0,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_two_selection":"select","related_content_item_two":{"ID":6886,"post_author":"974","post_date":"2023-07-13 11:16:33","post_date_gmt":"2023-07-13 09:16:33","post_content":"<!-- wp:acf\/article-hero-block {\"id\":\"block_6332060eef44a\",\"name\":\"acf\/article-hero-block\",\"data\":{\"date_text\":\"\",\"_date_text\":\"mco_f1_date_text\",\"share_text\":\"\",\"_share_text\":\"mco_f1_share_text\"},\"align\":\"\",\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>Notre site de Schachen joue un r\u00f4le cl\u00e9 dans le d\u00e9veloppement de nouveaux m\u00e9dicaments novateurs. Depuis sa cr\u00e9ation en 1976, le site a connu une croissance continue. Il compte d\u00e9sormais quelque 490 collaborateurs provenant de 30 pays. <\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2>Voici ce que nous faisons \u00e0 Schachen:<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:mccberg\/f7-listicle {\"className\":\"mt-2\"} -->\n<div class=\"wp-block-mccberg-f7-listicle mco-f7-block wrapper-story-narrower mt-2\"><!-- wp:mccberg\/f7-listicle-item {\"className\":\"mt-2\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item mt-2\"><div class=\"f7-listicle-header\"><div><\/div><div><p>01.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3>Nous fabriquons des principes actifs biotechnologiques.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>\u00c0 Schachen, nous disposons d'une production biotechnologique \u00e0 l'\u00e9chelle clinique pour la fabrication de nouveaux principes actifs, ainsi que de capacit\u00e9s de remplissage st\u00e9rile de nouveaux m\u00e9dicaments.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"10px\"} -->\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:image {\"id\":6889,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2023\/07\/Stainless-Steel-Bioreactor1.jpg?w=1000\" alt=\"Bior\u00e9acteur en acier inoxydable\" class=\"wp-image-6889\" \/><figcaption>Bior\u00e9acteur en acier inoxydable<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"02.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>02.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3>Nous fournissons des m\u00e9dicaments pour des \u00e9tudes cliniques internationales.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Schachen est l'un des deux seuls sites du r\u00e9seau international de MSD \u00e0 fournir de nouveaux m\u00e9dicaments pour des \u00e9tudes cliniques dans le monde entier. Les \u00e9chantillons de test cliniques y sont emball\u00e9s, \u00e9tiquet\u00e9s puis envoy\u00e9s \u00e0 des centres cliniques \u00e0 travers le monde. Les \u00e9tudes strictement contr\u00f4l\u00e9es montrent si les nouveaux m\u00e9dicaments sont efficaces et s\u00fbrs.<\/p>\n<!-- \/wp:paragraph --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"03.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>03.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3>Nous d\u00e9veloppons des m\u00e9thodes analytiques pour de nouveaux principes actifs et m\u00e9dicaments.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Le d\u00e9veloppement analytique est l'un de nos secteurs cl\u00e9s. Dans diff\u00e9rents laboratoires sp\u00e9ciaux, nous analysons des cultures cellulaires, r\u00e9alisons des tests avec des essais biologiques et fournissons tous les \u00e9l\u00e9ments n\u00e9cessaires au d\u00e9veloppement de m\u00e9thodes d'analyse pour de nouveaux principes actifs et m\u00e9dicaments, des tests PCR aux analyses biochimiques, en passant par la spectroscopie de masse.<\/p>\n<!-- \/wp:paragraph --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"04.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>04.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3>Nous travaillons sur des m\u00e9thodes d'analyse permettant de contr\u00f4ler et g\u00e9rer sans interruption un processus de production continu.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>En raison des exigences techniques et r\u00e9glementaires tr\u00e8s \u00e9lev\u00e9es, les processus de production continus sont encore rares dans le secteur pharmaceutique.<\/p>\n<!-- \/wp:paragraph --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"05.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>05.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3>Nous disposons d'un laboratoire d'analyse judiciaire permettant d'investiguer les suspicions de contrefa\u00e7ons de m\u00e9dicaments.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>\u00c0 Schachen, nous disposons de l'un des trois laboratoires d'analyse judiciaire au monde visant \u00e0 d\u00e9tecter rapidement les manipulations et contrefa\u00e7ons de produits MSD. \u00c0 l'aide de m\u00e9thodes analytiques et d'instruments hautement sp\u00e9cialis\u00e9s, nos scientifiques s'emploient \u00e0 distinguer les contrefa\u00e7ons des produits originaux et, le cas \u00e9ch\u00e9ant, \u00e0 t\u00e9moigner au tribunal en tant qu'experts dans le cadre de poursuites judiciaires. Ils visent \u00e9galement \u00e0 optimiser la protection des produits MSD contre la contrefa\u00e7on \u00e0 l'\u00e9chelle mondiale. <\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"10px\"} -->\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:image {\"id\":6890,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2023\/07\/MSD_lab_21.jpg?w=3840\" alt=\"MSD Schachen: laboratoire d'analyse judiciaire\" class=\"wp-image-6890\" \/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:spacer {\"height\":\"10px\"} -->\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item --><\/div>\n<!-- \/wp:mccberg\/f7-listicle -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:pullquote {\"fontSize\":\"small\"} -->\n<figure class=\"wp-block-pullquote has-small-font-size\"><blockquote><p>\u00ab<em>Le site de Schachen ne repose pas seulement sur la technologie la plus moderne et des recherches novatrices, mais aussi et surtout sur les personnes. Je suis tr\u00e8s fi\u00e8re de notre \u00e9quipe, qui s'emploie avec passion et engagement \u00e0 am\u00e9liorer la vie des patientes et des patients avec des d\u00e9couvertes r\u00e9volutionnaires et le d\u00e9veloppement de nouveaux m\u00e9dicaments. Leur engagement infatigable fait de Schachen le lieu o\u00f9 nous pouvons atteindre des sommets, tous ensemble<\/em>.\u00bb<\/p><cite>DR. CORINNA LENZ, DIRECTRICE DU SITE MSD DE SCHACHEN<\/cite><\/blockquote><\/figure>\n<!-- \/wp:pullquote -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:spacer -->\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:paragraph {\"align\":\"right\"} -->\n<p class=\"has-text-align-right\"><sup>CH-NON-02294, 07\/2023<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Au c\u0153ur de Schachen: un aper\u00e7u de notre centre de d\u00e9veloppement technologique de pointe","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"au-coeur-de-schachen-un-apercu-de-notre-centre-de-developpement-technologique-de-pointe","to_ping":"","pinged":"","post_modified":"2026-02-16 21:30:22","post_modified_gmt":"2026-02-16 19:30:22","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.msd.ch\/fr\/?post_type=story&p=6886","menu_order":0,"post_type":"story","post_mime_type":"","comment_count":"0","filter":"raw"},"story_three_selection":"select","related_content_item_three":{"ID":6452,"post_author":"282","post_date":"2023-04-17 22:39:30","post_date_gmt":"2023-04-17 20:39:30","post_content":"<!-- wp:acf\/article-hero-block {\"name\":\"acf\/article-hero-block\",\"data\":{\"date_text\":\"31 March 2023\",\"_date_text\":\"mco_f1_date_text\",\"share_text\":\"\",\"_share_text\":\"mco_f1_share_text\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:paragraph -->\n<p>\u00c0 l\u2019occasion de la Journ\u00e9e mondiale de sensibilisation aux HPV, le 4 mars, <a href=\"https:\/\/www.msd.ch\/fr\/home\/about-us\/leadership\/\">notre direction<\/a> a convi\u00e9 tous les collaborateurs de MSD \u00e0 un d\u00e9jeuner de formation avec le Dr Alina Staikov. Cette gyn\u00e9cologue est tr\u00e8s impliqu\u00e9e dans la lutte contre le cancer et s\u2019engage pour l\u2019information, le traitement, la pr\u00e9vention et le d\u00e9pistage.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Quel est le lien entre le cancer et l'HPV ? Les papillomavirus humains peuvent, dans certains cas, provoquer un cancer. La bonne nouvelle est que les personnes inform\u00e9es peuvent se prot\u00e9ger contre les HPV et pr\u00e9venir les cancers qui y sont li\u00e9s, ou les faire traiter \u00e0 temps!<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Chez MSD, nous nous engageons pour la pr\u00e9vention et le d\u00e9pistage du cancer<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>En tant qu\u2019entreprise pharmaceutique leader dans le domaine de l\u2019oncologie, nous ne nous contentons pas d\u2019informer le public, mais traduisons nos paroles en actes. C\u2019est pourquoi nous organisons r\u00e9guli\u00e8rement des \u00e9v\u00e9nements internes pour nous former, en l\u2019occurrence sur les HPV et leurs cons\u00e9quences sur la sant\u00e9. Plus de 50 coll\u00e8gues de l\u2019ensemble des succursales suisses ont profit\u00e9 de l\u2019occasion pour en apprendre davantage et poser leurs questions au Dr Staikov.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Les HPV peuvent provoquer certains types de cancers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Dr Staikov a pr\u00e9sent\u00e9 les principaux faits concernant l'HPV. Elle a expliqu\u00e9, entre autres, que ces virus sont tr\u00e8s r\u00e9pandus et que m\u00eame les adolescents devraient en \u00eatre inform\u00e9s, car les jeunes peuvent aussi \u00eatre infect\u00e9s. Elle a \u00e9galement expliqu\u00e9 que presque tout le monde est expos\u00e9 aux HPV au cours de sa vie et d\u00e9crit ce qui peut arriver si le virus ne dispara\u00eet pas de lui-m\u00eame. Dr Staikov a donc particuli\u00e8rement soulign\u00e9 les possibilit\u00e9s de pr\u00e9vention et de d\u00e9pistage pr\u00e9coce. Nous avons aussi pu poser des questions, ce qui a rendu l\u2019\u00e9v\u00e9nement interactif et vivant. Que retenir et quels messages rapporter chez soi? D\u00e9couvrez-le dans la section suivante!<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Cinq faits que tout le monde devrait conna\u00eetre sur les HPV<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:list {\"ordered\":true} -->\n<ol class=\"wp-block-list\"><!-- wp:list-item -->\n<li>Les papillomavirus humains (HPV) sont tr\u00e8s r\u00e9pandus et peuvent survenir aussi bien chez les adolescents que chez les adultes.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>La contamination par les HPV se fait de personne \u00e0 personne, par contact avec la peau et les muqueuses.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>Les HPV peuvent provoquer certains types de cancers et certaines l\u00e9sions pr\u00e9canc\u00e9reuses.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>Les cancers les plus fr\u00e9quents li\u00e9s aux HPV sont le cancer du col de l\u2019ut\u00e9rus, le cancer de l\u2019anus et le cancer de la bouche et de la gorge.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>Les rapports sexuels prot\u00e9g\u00e9s et la vaccination peuvent contribuer \u00e0 la pr\u00e9vention de certaines maladies li\u00e9es aux HPV.<\/li>\n<!-- \/wp:list-item --><\/ol>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><!-- wp:image {\"id\":6272,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/01\/HPV-Virus-Cervical-800x800-AdobeStock_409343974.jpg?w=800\" alt=\"Illustration HPV Virus\" class=\"wp-image-6272\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"medium\"} -->\n<p class=\"has-text-align-center has-medium-font-size\"><strong>\u00ab<\/strong> <em><strong>Il est primordial que les gens soient inform\u00e9s. \u00c0 d\u00e9faut d\u2019information, ils ne peuvent pas prendre de d\u00e9cisions et n\u2019ont pas de choix. \u00bb<\/strong><\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7481,\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/04\/AlinaStaikov.png?w=800\" alt=\"Dr. Alina Staikov\" class=\"wp-image-7481\"\/><figcaption class=\"wp-element-caption\">Dr Alina Staikov<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7482,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/04\/Presentation.png\" alt=\"The stage at the Lunch & Learn about HPV\" class=\"wp-image-7482\"\/><figcaption class=\"wp-element-caption\">Pendant l\u2019\u00e9v\u00e9nement<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7483,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/04\/Audience.png\" alt=\"MSD employees \" class=\"wp-image-7483\"\/><figcaption class=\"wp-element-caption\">Applaudissements pour le Dr Staikov<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:paragraph -->\n<p>L\u2019\u00e9v\u00e9nement nous a offert une formidable opportunit\u00e9 d\u2019apprendre en \u00e9quipe et de vivre notre culture MSD.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><!-- wp:image {\"id\":8339,\"width\":\"216px\",\"height\":\"auto\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/04\/HPV-info.jpg\" alt=\"\" class=\"wp-image-8339\" style=\"width:216px;height:auto\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Vous souhaitez en savoir plus sur les HPV?<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Plus d\u2019informations \u00e0 destination des parents, des femmes et des hommes:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><strong><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/hpv-info\">En savoir plus<\/a><\/strong><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Vous souhaitez en savoir plus sur le cancer du col de l\u2019ut\u00e9rus?<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Plus d\u2019informations sur la maladie et son traitement<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><strong><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-du-col-de-luterus\">Informations \u00e0 destination des femmes<\/a><\/strong><u><strong><br><\/strong><\/u><strong><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indikationen\/cervix\/\">Informations \u00e0 destination des m\u00e9decins<\/a><\/strong><br><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><!-- wp:image {\"id\":6274,\"width\":\"208px\",\"height\":\"auto\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/01\/Cervical-Cancer-gettyimages-583914445-170667a.jpg?w=800\" alt=\"Mutter und Tochter laufen nebeneinander Arm in Arm\" class=\"wp-image-6274\" style=\"width:208px;height:auto\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-02171, 02\/2025<\/sup><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->","post_title":"Joindre le geste \u00e0 la parole: d\u00e9jeuner de formation sur les HPV","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"dejeuner-de-formation-sur-les-hpv","to_ping":"","pinged":"","post_modified":"2025-05-02 08:25:48","post_modified_gmt":"2025-05-02 06:25:48","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.msd.ch\/fr\/?post_type=story&p=6452","menu_order":0,"post_type":"story","post_mime_type":"","comment_count":"0","filter":"raw"},"scroll-to-top":false,"subheader_title":"Le cancer du sein est le cancer le plus fr\u00e9quent chez les femmes. Plus le cancer du sein est d\u00e9pist\u00e9 et trait\u00e9 pr\u00e9cocement, plus les chances de gu\u00e9rison sont \u00e9lev\u00e9es. Chez MSD, nous nous engageons \u00e0 renforcer le d\u00e9pistage et la d\u00e9tection pr\u00e9coce de ces cancers. C\u2019est pourquoi nous avons lanc\u00e9 en 2022 le PINK CUBE: une initiative de sensibilisation au cancer du sein, qui ne cesse de se d\u00e9velopper depuis. PINK CUBE a d\u00e9j\u00e0 re\u00e7u deux prix et cela fait notre fiert\u00e9!","secondary_image":false,"video_hosting_selection":"youtube","youtube_url":"","video_accessible_name":"","primary_cta":"Read more","primary_cta_aria_label":"","secondary_cta":"","secondary_cta_aria_label":"","mcc_page_job_number":"","show_image_captions":false,"related_content_item_one_aria_label":"","related_content_item_two_aria_label":"","related_content_item_three_aria_label":""}},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story\/8316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/story"}],"version-history":[{"count":9,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story\/8316\/revisions"}],"predecessor-version":[{"id":9001,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story\/8316\/revisions\/9001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media\/8317"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=8316"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/tags?post=8316"},{"taxonomy":"content_topic","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/content_topic?post=8316"},{"taxonomy":"Admin Field","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/admin_field?post=8316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}